TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck

Radiotherapy and Oncology

Volumn 59, Issue 2, 2001, Pages 179-185

  Alsner, Jan ^a   Sørensen, Susanne Berg ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Head and neck cancer; Prognostic factor; Radiotherapy; TP53 mutation

Indexed keywords

NIMORAZOLE; PROTEIN P53; RADIOSENSITIZING AGENT;

ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FRAMESHIFT MUTATION; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTIMODALITY CANCER THERAPY; NONSENSE MUTATION; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; FEMALE; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; MUTATION; PHARYNGEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0342973089     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(01)00301-2     Document Type: Article

References (37)

1. Ahomadegbe J.C., Barrois M., Fogel S., et al. High incidence of p53 alterations (mutation, deletion, over-expression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein over-expression in normal epithelium and in early non-invasive lesions. Oncogene. 10:1995;1217-1227.
2. Alsner J., Høyer M., Sørensen S.B., Overgaard J. Interaction between potential doubling time and TP53 mutation: predicting radiotherapy outcome in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 49:2001;519-525.
3. Begg A.C., Haustermans K., Hart A.A., et al. The value of pre-treatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol. 50:1999;13-23.
4. Bjørk-Eriksson T., West C., Karlsson E., Mercke C. Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int J Radiat Oncol Biol Phys. 46:2000;13-19.
5. Blencowe B.J. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci. 25:2000;106-110.
6. Bradford C.R. Predictive factors in head and neck cancer. Hematol Oncol Clin North Am. 13:1999;777-785.
7. Brown J.M., Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1999;1391-1399.
8. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:1994;346-355.
9. Chomchai J.S., Du W., Sarkar F.H., et al. Prognostic significance of p53 gene mutations in laryngeal cancer. Laryngoscope. 109:1999;455-459.
10. Erber R., Conradt C., Homann N., et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene. 16:1998;1671-1679.
11. Eschwege F., Bourhis J., Girinski T., et al. Predictive assays of radiation response in patients with head and neck squamous cell carcinoma: a review of the Institute Gustave Roussy experience. Int J Radiat Oncol Biol Phys. 39:1997;849-853.
12. Finkel E. Does cancer therapy trigger cell suicide? Science. 286:1999;2256-2258.
13. Gallo O., Chiarelli I., Boddi V., Bocciolini C., Bruschini L., Porfirio B. Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer. 84:1999;573-579.
14. Ganly I., Soutar D.S., Brown R., Kaye S.B. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. Br J Cancer. 82:2000;392-398.
15. Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 92:2000;709-720.
16. Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V., Zeuthen J. Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat. 9:1997;348-355.
17. Hainaut P., Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 77:2000;81-137.
18. Hansen O., Overgaard J., Sand Hansen H., et al. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol. 43:1997;47-51.
19. Hegde P.U., Brenski A.C., Caldarelli D.D., et al. Tumor angiogenesis and p53 mutations: prognosis in head and neck cancer. Arch Otolaryngol Head Neck Surg. 124:1998;80-85.
20. Khuri F.R., Nemunaitis J., Ganly I., et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 6:2000;879-885.
21. Koch W.M., Brennan J.A., Zahurak M., et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst. 88:1996;1580-1586.
22. Koch W.M., Lango M., Sewell D., Zahurak M., Sidransky D. Head and neck cancer in non-smokers: a distinct clinical and molecular entity. Laryngoscope. 109:1999;1544-1551.
23. Lowe S.W., Bodis S., McClatchey A., et al. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
24. Ma L., Ronai A., Riede U.N., Kohler G. Clinical implication of screening p53 gene mutations in head and neck squamous cell carcinomas. J Cancer Res Clin Oncol. 124:1998;389-396.
25. Mineta H., Borg A., Dictor M., Wahlberg P., Akervall J., Wennerberg J. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer. 78:1998;1084-1090.
26. Moore M.J. Intron recognition comes of AGe. Nat Struct Biol. 7:2000;14-16.
27. Overgaard J., Sand Hansen H., Overgaard M., et al. Importance of overall treatment time for the outcome of radiotherapy in head and neck carcinoma. Experience from the Danish Head and Neck Cancer Study. Kogelnik H.D., Sedlmeyer F., et al. Progress in radio-oncology. 1998;743-752 Monduzzi Editore, Bologna.
28. Prives C., Hall P.A. The p53 pathway. J Pathol. 187:1999;112-126.
29. Raybaud-Diogène H., Tétu B., Morency R., Fortin A., Monteil R.A. p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Eur J Cancer B Oral Oncol. 32B:1996;143-149.
30. Riethdorf S., Friedrich R.E., Ostwald C., et al. p53 gene mutations and HPV infection in primary head and neck squamous cell carcinomas do not correlate with overall survival: a long term follow-up study. J Oral Pathol Med. 26:1997;315-321.
31. Rogulski K.R., Freytag S.O., Zhang K., et al. In vivo anti-tumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 60:2000;1193-1196.
32. Rupnow B.A., Murtha A.D., Alarcon R.M., Giaccia A.J., Knox S.J. Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res. 58:1998;1779-1784.
33. Saunders M.E., MacKenzie R., Shipman R., Fransen E., Gilbert R., Jordan R.C. Patterns of p53 gene mutations in head and neck cancer: full-length gene sequencing and results of primary radiotherapy. Clin Cancer Res. 5:1999;2455-2463.
34. Stausbøl-Grøn B., Overgaard J. Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck. Radiother Oncol. 50:1999;47-55.
35. Taylor D., Koch W.M., Zahurak M., Shah K., Sidransky D., Westra W.H. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol. 30:1999;1221-1225.
36. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
37. Withers H.R., Taylor J.M., Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27:1988;131-146.